Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKX019 in Autoimmune Diseases (Lupus Nephritis and Primary Membranous Nephropathy)
NCT06557265Phase 2Recruiting
- Sponsor
- Nkarta
- Start
- Jun 2024
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 3
01
Overview
A Phase 2 trial of NKX019 in lupus nephritis (LN), primary membranous nephropathy (PMN), sponsored by Nkarta. Started Jun 2024; status: recruiting.
02
Drugs
NKX019
03
Conditions
lupus nephritis (LN)primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT06557265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557265.